With the rapid advancements in medical research, diagnostic technology and increased public health initiative and awareness, overall cancer death rates in western societies are declining each year with the number of deaths from major cancers such as breast, colorectal and lung following this trend. However, the survival rate for those with pancreatic cancer has been at a standstill for over four decades and there are concerns that pancreatic cancer may become the second deadliest cancer in the US by the year 2030. The diagnosis of pancreatic cancer has dire consequences as it presents late in its course and is rapidly progressive. This is clearly one of the most devastating of human cancers, and as there are very few treatment options for those with the disease, new approaches and novel therapeutic strategies are urgently required. For thousands of years, plants have been used as traditional indigenous remedies for a variety of ailments in many parts of the world. It is thought that approximately 80% of the rural population worldwide still relies on plants as medicines. Plants have assumed the greatest prominence as a source of medicinal compounds with thousands of species associated with the treatment of cancers or conditions with cancer-like symptoms. Scientific evaluation of a range of traditional medicines has led to the development of highly effective cancer therapeutic agents, and it is estimated that approximately 50% of all pharmaceuticals currently available for administration are still derived from natural origins. With this in mind, within the plant kingdom there remains great potential for the development of novel therapeutic agents with significant efficacy against pancreatic cancer. With our increasing understanding of the molecular pathology of pancreatic cancer and the rapid advancement of DNA sequencing technology to understand the structure of the genome and infer biology, pancreatic cancer is one of the most appropriate diseases to test multiple novel plant derived therapeutics in a molecular phenotype driven personalised approach.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USA
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Bestandsnummer des Verkäufers ABBB-75616
Anbieter: Books Puddle, Woodside, NY, USA
Zustand: New. Index. Bestandsnummer des Verkäufers 26323870824
Anzahl: 4 verfügbar
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
Zustand: New. Bestandsnummer des Verkäufers 322592695
Anzahl: 4 verfügbar
Anbieter: Biblios, Frankfurt am main, HESSE, Deutschland
Zustand: New. Bestandsnummer des Verkäufers 18323870818
Anzahl: 4 verfügbar
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: New. Bestandsnummer des Verkäufers 22081632-n
Anzahl: 1 verfügbar
Anbieter: PBShop.store US, Wood Dale, IL, USA
HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Bestandsnummer des Verkäufers GZ-9781634633246
Anbieter: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irland
Zustand: New. Editor(s): Vuong, Quan V.; Scarlett, Christopher J. Num Pages: 330 pages. BIC Classification: MJCL. Category: (P) Professional & Vocational. Dimension: 186 x 262 x 23. Weight in Grams: 754. . 2014. 1st Edition. Hardcover. . . . . Bestandsnummer des Verkäufers V9781634633246
Anzahl: 1 verfügbar
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000. Bestandsnummer des Verkäufers GZ-9781634633246
Anzahl: 1 verfügbar
Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes Königreich
Zustand: New. Bestandsnummer des Verkäufers 22081632-n
Anzahl: 1 verfügbar
Anbieter: GreatBookPrices, Columbia, MD, USA
Zustand: As New. Unread book in perfect condition. Bestandsnummer des Verkäufers 22081632
Anzahl: 1 verfügbar